Literature DB >> 16997711

Lyophilisation and sterilisation of liposomal vaccines to produce stable and sterile products.

Afzal R Mohammed1, Vincent W Bramwell, Allan G A Coombes, Yvonne Perrie.   

Abstract

The advantages of liposomes as delivery systems for peptide, protein and DNA vaccines is well-recognised, unfortunately their application has been stinted by their instability during storage and their limited shelf-life. Further, sterilisation of these systems has been problematic, with degradation of the liposomes being reported after sterilisation using the various techniques available. Work form our laboratory has investigated techniques that can be applied to particulate liposomal vaccines such that they can be prepared in a freeze-dried and sterile format. In this article, we describe techniques for the lyophilisation, cryoprotection and sterilisation of liposomal vaccines. Applying these methods allows for the retention of both the chemical integrity of the lipids and the key physico-chemical characteristics of the liposomes (e.g., particle size, zeta potential, and dynamic viscosity), thus supporting the enhanced transition of liposomal vaccines from the bench to the clinic.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16997711     DOI: 10.1016/j.ymeth.2006.05.025

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  13 in total

Review 1.  Radiation sterilization of new drug delivery systems.

Authors:  Gürhan Abuhanoğlu; A Yekta Ozer
Journal:  Interv Med Appl Sci       Date:  2014-06-04

Review 2.  Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses.

Authors:  Moses O Oyewumi; Amit Kumar; Zhengrong Cui
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

Review 3.  A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant.

Authors:  Yvonne Perrie; Elisabeth Kastner; Randip Kaur; Alexander Wilkinson; Andrew J Ingham
Journal:  Hum Vaccin Immunother       Date:  2013-04-12       Impact factor: 3.452

4.  Gamma-irradiated liposome/noisome and lipogelosome/niogelosome formulations for the treatment of rheumatoid arthritis.

Authors:  Selcan Turker; A Yekta Ozer; Ekrem Kiliç; Meral Ozalp; Seyda Colak; Mustafa Korkmaz
Journal:  Interv Med Appl Sci       Date:  2013-07-04

5.  The effects of gamma irradiation on diclofenac sodium, liposome and niosome ingredients for rheumatoid arthritis.

Authors:  A Yekta Ozer; Selcan Turker; Seyda Colak; Mustafa Korkmaz; Ekrem Kiliç; Meral Ozalp
Journal:  Interv Med Appl Sci       Date:  2013-09-16

6.  Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses.

Authors:  James J Moon; Heikyung Suh; Anna Bershteyn; Matthias T Stephan; Haipeng Liu; Bonnie Huang; Mashaal Sohail; Samantha Luo; Soong Ho Um; Htet Khant; Jessica T Goodwin; Jenelyn Ramos; Wah Chiu; Darrell J Irvine
Journal:  Nat Mater       Date:  2011-02-20       Impact factor: 43.841

Review 7.  Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines.

Authors:  Luis O De Serrano; David J Burkhart
Journal:  J Nanobiotechnology       Date:  2017-11-17       Impact factor: 10.435

8.  Development of a solid dosage platform for the oral delivery of bilayer vesicles.

Authors:  Jitinder S Wilkhu; Sarah E McNeil; David E Anderson; Marc Kirchmeier; Yvonne Perrie
Journal:  Eur J Pharm Sci       Date:  2017-06-12       Impact factor: 4.384

Review 9.  Lyophilization of Liposomal Formulations: Still Necessary, Still Challenging.

Authors:  Silvia Franzé; Francesca Selmin; Elena Samaritani; Paola Minghetti; Francesco Cilurzo
Journal:  Pharmaceutics       Date:  2018-08-28       Impact factor: 6.321

10.  Silica-based cationic bilayers as immunoadjuvants.

Authors:  Nilton Lincopan; Mariana Ra Santana; Eliana Faquim-Mauro; Maria Helena B da Costa; Ana M Carmona-Ribeiro
Journal:  BMC Biotechnol       Date:  2009-01-19       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.